Your browser doesn't support javascript.
loading
SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility.
Zhou, Bin; Thao, Tran Thi Nhu; Hoffmann, Donata; Taddeo, Adriano; Ebert, Nadine; Labroussaa, Fabien; Pohlmann, Anne; King, Jacqueline; Portmann, Jasmine; Halwe, Nico Joel; Ulrich, Lorenz; Trüeb, Bettina Salome; Kelly, Jenna N; Fan, Xiaoyu; Hoffmann, Bernd; Steiner, Silvio; Wang, Li; Thomann, Lisa; Lin, Xudong; Stalder, Hanspeter; Pozzi, Berta; de Brot, Simone; Jiang, Nannan; Cui, Dan; Hossain, Jaber; Wilson, Malania; Keller, Matthew; Stark, Thomas J; Barnes, John R; Dijkman, Ronald; Jores, Joerg; Benarafa, Charaf; Wentworth, David E; Thiel, Volker; Beer, Martin.
Affiliation
  • Zhou B; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Thao TTN; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Hoffmann D; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Taddeo A; Graduate School for Biomedical Science, University of Bern, Bern, Switzerland.
  • Ebert N; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Labroussaa F; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Pohlmann A; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • King J; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Portmann J; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Halwe NJ; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Ulrich L; Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Trüeb BS; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Kelly JN; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Fan X; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Hoffmann B; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Steiner S; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Wang L; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Thomann L; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Lin X; Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Stalder H; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Pozzi B; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • de Brot S; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Jiang N; Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Cui D; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Hossain J; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Wilson M; Graduate School for Biomedical Science, University of Bern, Bern, Switzerland.
  • Keller M; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Stark TJ; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Barnes JR; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Dijkman R; Battelle Memorial Institute, Atlanta, Georgia, United States of America.
  • Jores J; Institute of Virology and Immunology (IVI), Bern and Mittelhäusern, Switzerland.
  • Benarafa C; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Wentworth DE; Institute of Cell Biology, University of Bern, Bern, Switzerland.
  • Thiel V; COMPATH, Institute of Animal Pathology, University of Bern, Bern, Switzerland.
  • Beer M; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States of America.
bioRxiv ; 2020 Oct 27.
Article in En | MEDLINE | ID: mdl-33140052
During the evolution of SARS-CoV-2 in humans a D614G substitution in the spike (S) protein emerged and became the predominant circulating variant (S-614G) of the COVID-19 pandemic 1 . However, whether the increasing prevalence of the S-614G variant represents a fitness advantage that improves replication and/or transmission in humans or is merely due to founder effects remains elusive. Here, we generated isogenic SARS-CoV-2 variants and demonstrate that the S-614G variant has (i) enhanced binding to human ACE2, (ii) increased replication in primary human bronchial and nasal airway epithelial cultures as well as in a novel human ACE2 knock-in mouse model, and (iii) markedly increased replication and transmissibility in hamster and ferret models of SARS-CoV-2 infection. Collectively, our data show that while the S-614G substitution results in subtle increases in binding and replication in vitro , it provides a real competitive advantage in vivo , particularly during the transmission bottle neck, providing an explanation for the global predominance of S-614G variant among the SARS-CoV-2 viruses currently circulating.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: BioRxiv Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: BioRxiv Year: 2020 Type: Article Affiliation country: United States